DelMar Pharmaceuticals Inc  

(Public, OTCMKTS:DMPI)   Watch this stock  
Find more results for Jeffrey Garner
+0.050 (5.62%)
Nov 21 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.89 - 0.99
52 week 0.62 - 1.60
Open 0.89
Vol / Avg. 32,514.00/28,828.00
Mkt cap 31.87M
P/E     -
Div/yield     -
EPS -0.16
Shares 32.60M
Beta     -
Inst. own 0%
Sep 11, 2014
DelMar Pharmaceuticals Inc at SeeThruEquity Fall Microcap Investor Conference
Sep 9, 2014
DelMar Pharmaceuticals Inc at Rodman & Renshaw Global Investment Conference

Key stats and ratios

Q3 (Sep '14) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -111.65% -
Return on average equity -944.70% -
Employees 4 -
CDP Score - -


Suite 720 999 West Broadway
+1-604-6295989 (Phone)

Website links


DelMar Pharmaceuticals, Inc. formerly Berry Only Inc., is developing new drug candidates targeting orphan cancer indications. The Company�s product development programs VAL-083 is approved as a cancer chemotherapeutic in China for the treatment of chronic myelogenous leukemia and solid tumors, including lung cancer. The Company has opened an Investigational New Drug (IND) with the United States Food & Drug Administration (FDA) to begin Phase II human clinical trials with VAL-083 in patients suffering from glioblastoma multiforme (GBM). Glioblastoma multiforme (GBM) is the common and malignant form of brain cancer.

Officers and directors

Jeffrey A. Bacha President, Chief Executive Officer, Director
Scott Praill Chief Financial Officer
Age: 46
Dennis M. Brown Ph.D. Chief Scientific Officer, Director
Age: 64
William J. Garner M.D. Director
Robert J Toth Jr Director
Age: 50
John K. Bell Independent Director